ScripAkeso has garnered a regulatory nod for penpulimab from the US Food and Drug Administration, making the agent the second PD-1 checkpoint inhibitor originating from a Chinese drug maker in the US marke
In VivoOne of the main topics of conversation at the beginning of 2025 is how pharma companies should build their pipelines and the rising role that China is playing. A widely-cited report from Stifel show
ScripAstraZeneca ended last year as the world’s seventh largest pharma company by market cap – but as the leading group when it comes to starting clinical trials. Last year AstraZeneca kicked off 139 tri
ScripInnovent Biologics, Inc. and GenFleet Therapeutics on 21 August scored China’s first approval for a KRAS G12C inhibitor, the co-developed Dupert (fulzerasib), winning a head start over foreign and